We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

NB-UVB and PUVA Vitiligo Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01732965
Recruitment Status : Completed
First Posted : November 26, 2012
Last Update Posted : February 23, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
To evaluate if the combination of psoralen plus ultraviolet A and narrowband ultraviolet B is more effective than narrowband ultraviolet B alone in the treatment of vitiligo.

Condition or disease Intervention/treatment Phase
Vitiligo Other: Phototherapy Other: Phototherapy and Photochemotherapy Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo
Study Start Date : March 2013
Primary Completion Date : January 2014
Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: NB-UVB phototherapy
NB-UVB alone
Other: Phototherapy
Experimental: phototherapy and photochemotherapy
NB-UVB and PUVA
Other: Phototherapy and Photochemotherapy


Outcome Measures

Primary Outcome Measures :
  1. Determine the quantity of repigmentation [ Time Frame: 6 months ]
    Determination the degree of repigmentation measured by the VASI score (Vitiligo area Scoring Index) after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.


Secondary Outcome Measures :
  1. Determine the quality of repigmentation. [ Time Frame: Study initiation, 3 months and 6 months. ]
    Determination of the color of repigmentation, pattern of repigmentation, and the cessation of spread of vitiligo after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Vitiligo affecting more than 15% body surface area.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01732965


Locations
United States, Michigan
Henry Ford Dermatology
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Iltefat Hamzavi, MD Henry Ford Dermatology
More Information

Responsible Party: Iltefat Hamzavi, Senior Staff Physician, Henry Ford Health System
ClinicalTrials.gov Identifier: NCT01732965     History of Changes
Other Study ID Numbers: HFHS Vitiligo Phototherapy
First Posted: November 26, 2012    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017

Keywords provided by Iltefat Hamzavi, Henry Ford Health System:
Vitiligo
Phototherapy
Photochemotherapy

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases